Introduction
Allogeneic hematopoietic stem cell transplantation (HSCT) is the only therapeutic option for many hematological malignancies. For patients without human leukocyte antigen (HLA)-matched sibling, unrelated bone marrow or cord blood is often used as the source of stem cells for transplantation. Unfortunately, this may be unavailable because of unsuccessful donor search or insufficient amount of cord blood cells. The alternative is hematopoietic stem cells from an HLA-mismatched family donor. However, this attempt, especially before the end of last decade, was associated poor engraftment, high risk of early death and severe graft-versus-host disease (GVHD). [1] [2] [3] The approach of T-cell depletion (TCD) or CD34 þ cell selection in vitro overcame the HLA barrier but was also confronted with delayed immune reconstitution. 4 Here, we describe a method for haploidentical allogeneic hematopoietic stem cell transplantation (allo-HSCT) from family members without in vitro TCD, which is designed to overcome HLA barriers and reduce complications. This method involves sequential, in vivo modulation of T-cell functions in the recipient and the donor, and adjustment of the dose of donor HSCs. There are four elements in this protocol: granulocyte-colony stimulating factor (G-CSF) for all donors, intensive immune suppression, anti-human thymocyte immunoglobulin (ATG), combination of G-CSF primed peripheral blood (PBSCs) and bone marrow stem cells (G-BM).
Patients and methods

Patient eligibility
One hundred and seventy-one patients with malignant hematological disease underwent haploidentical allo-HSCT between July 2000 and February 2005. We enrolled patients with hematological malignancies suitable for allo-HSCT, who had no HLA-identical related or unrelated donors. The Institutional Review Board of Peking University approved this study, and all patients and their donors gave written informed consent. Characteristics of the 171 patients and donors are summarized in Table 1 .
Donor and stem cell harvesting
Family donors were ranked on the basis of best HLA match, age (younger preferred), relationship (mother preferred), gender (same preferred), and health status (better preferred). For HLA-A and B, low-resolution DNA techniques were used. High-resolution techniques were used to define class II antigens.
Donors were primed with rhG-CSF (Filgrastim, Kirin, Japan; 5 mg/kg per day) injected subcutaneous (s.c.) for five to six consecutive days. On the fourth day, bone marrow cells were harvested. The target mononuclear cell count (MNC) was 3 Â 10 8 -4 Â 10 8 cells/kg recipient weight. On the fifth and sixth day, PBSCs were collected with a COBE Blood Cell Separator (Spectra LRS, COBE BCT Inc., Lakewood, CO, USA) at a rate of 80 ml/min from a total blood volume of 10 l. The fresh and unmanipulated bone marrow and PBSCs were infused into the recipient on the day of collection. In instances of ABO major blood group incompatibility, red cells were removed from bone marrow cells by density gradient sedimentation with Hespan (B. Braun Medical Inc, Irvine, CA, USA), according to the manufacturer's instructions. Surface markers of the cells in graft were determined by two-or three-color staining using monoclonal antibodies specific for CD34, CD3, CD4 and CD8 cells, essentially as described by Liu et al.
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Conditioning regimen
The drugs administered before transplantation in the regimens described below were cytosine arabinoside (Ara-C), busulfan (Bu), cyclophosphamide (Cy), Simustine (Me-CCNU), and antihuman thymocyte immunoglobulin (ATG: 80 mg/kg i.v., porcine, the Bioproduct, Wuhan or 10 mg/kg i.v., rabbit, of the Sangstat product). One hundred sixty-seven patients were treated with regimen A, which consisted of Ara-C (4 g/m 2 /d, i.v.) on day À10 and À9, Bu (12 mg/kg p.o. in 12 doses) on day À8, À7 and À6, Cy (1.8 g/m 2 /d, i.v.) on day À5 and À4, Me-CCNU (250 mg/kg, i.v.) on day À3, and ATG (20 mg/kg/d i.v. of the Wuhan product or 2.5 mg/kg/d i.v. of the Sangstat product) on day À5 to À2. Four patients, 50 years old or older, were conditioned with regimen B, which was the same as regimen A, except for lower dosages of Bu (6-8 mg/kg) and Cy (1.0 g/m 2 /d).
GVHD prophylaxis
All transplant recipients received cyclosporine A (CsA), mycophenolate mofetil (MMF), and short-term methotrexate. The dosage of CsA was 2.5 mg/kg/d, i.v. from day 9 before transplantation until bowel function returned to normal. At that point, the patient was switched to oral CsA. MMF was administered orally, 0.5 g every 12 h, from day 9 before transplantation to day 30 after transplantation. The dosage of methotrexate was 15 mg/m 2 , administered i.v. on day 1, and 10 mg/m 2 on day 3, 6 and 11 after transplantation. Whole blood CsA concentration was monitored weekly using fluorescence polarization immunoassay and the dosage was adjusted to the blood concentration of 150-250 ng/ml. In case of no evidence of GVHD by day 40-50, CsA dosage was reduced gradually and discontinued around day 180. In case of occurrence of GVHD, CsA was continued.
Evaluation of engraftment and chimerism Engraftment was defined as maintenance of an absolute neutrophil count above 0.5 Â 10 9 /l for three consecutive days after the neutrophil nadir. Follow-up assessment was performed by cytogenetic analysis of bone marrow aspiration in the first, second, and third month after transplantation. Chimerism was determined by at least two of the three methods: DNA-based HLA typing, DNA fingerprinting of short tandem repeat, and chromosomal fluorescent in situ hybridization (FISH).
Supportive care
All patients were hospitalized in rooms with high-efficiency particle-arresting (HEPA) air filters, and all received antibiotic prophylaxis with oral trimethoprim-sulfamethoxazole, fluconazole and acyclovir. All blood products were irradiated before infusion. Human immunoglobulin (400 mg/kg) was given i.v. on day 1, 11, 21 and 31 after transplantation. Patients received transfusion of red blood cells if their hemoglobin levels were below 70 g/l, or transfusion of platelets if their platelet levels dropped below 20 Â 10 9 /l. G-CSF (5 mg/kg per day s.c.) was given to all recipients from day 6 after transplantation until their neutrophil count reached 0.5 Â 10 9 /l for three consecutive days.
Definition and statistics
Patients with malignancies were categorized as 'standardrisk' if they were in first or second complete remission (CR1 or CR2) of acute leukemia or in the chronic phase of chronic myelogenous leukemia (CML). Patients were classified as 'high-risk' if they were in more than the third complete remission (CR3) of acute leukemia, not in remission, had high-risk cytogenetics, 6 such as t(9;22) or t(4;11), CML beyond the first chronic phase or MDS-RAEB. The diagnosis and grading of GVHD was performed according to published criteria. 7 Time to GVHD was defined as the time from allo-HSCT to the onset of any grade of GVHD.
Patients were evaluated for acute GVHD after they engrafted successfully, and for chronic GVHD if they survived for at least 100 days after HSCT. Distributions for time-to-acute/chronic GVHD, time-to-relapse, survival, and leukemia-free survival (LFS) were evaluated using Kaplan-Meier analysis. 8 A cumulative incidence test was used to account for follow-up time and the competing risk of death from other causes. 9 Such variables were measured from the date of HSCT (day 0). Values were adjusted for engraftment at time of death if the patient did not engraft; for GVHD, survival and relapse at last follow-up. The end point of the last follow-up for all surviving patients was 25 November 2005. Unless otherwise specified, all reported P-values were based on two-sided hypothesis tests. Alpha was set at 0.05. A statistical software package (SPSS 11.5) was used for all analyses. 10 
Results
All donors tolerated the procedures, and no severe side effects occurred during either bone marrow harvest or leukapheresis. The characteristics of the 171 patients are shown in Table 1 . Although the desired ratio of bone marrow to peripheral blood progenitor cells was 1:1, the actual ratio each patient received varied from 2:1 to 1:2 ( Table 2 ). All patients achieved hematopoietic recovery after transplantation. The median time for myeloid engraftment was 12 days (range: 9-26 days) and for platelet 15 days (range: 8-151 days). There was no statistically significant association between the extent of HLA disparity and the time of engraftment.
Acute GVHD Among the 171 patients, 47 (27.5%). had no acute GVHD, 51 (29.8%) had grade I, 51 (29.8%) had grade II, nine (5.3%) had grade III and 13 (7.6%) had grade IV. At 100 days after transplantation, the cumulative incidence was 55.0% for grade II-IV acute GVHD, and 23.1% for grade III-IV acute GVHD. Factors that might influence the incidence of grade III-IV GVHD were analyzed, which included age and gender of the patients and donors, number of MNC and CD3 þ cells infused at transplantation, stage of disease before transplantation and HLA disparity. There was no risk factor except for age of the patients (P ¼ 0.044). Acute GVHD occurred in 27 of 39 patients with HLA mismatched in one locus, 45 of 66 patients mismatched in two loci and 52 of 66 patients mismatched in three loci. Grade III-IV acute GVHD was diagnosed in five of 39 patients with HLA mismatched in one locus, eight of 68 patients mismatched in two loci and nine of 68 patients mismatched in three loci. The cumulative incidences of total acute GVHD and grade III-IV acute GVHD with various HLA disparity in standardrisk and high-risk group are shown in Figure 1 .
Acute GVHD of grade II or higher was treated with methylprednisolone (0.5B1 mg/kg per day). GVHD manifesting in the skin was treated with methotrexate.
11 When there was inadequate or no response to primary therapy, anti-Tac monoclonal antibody (Daclizumab; Roche, Basel, Switzerland) was administered, 1 mg/kg i.v. on day 1, 4, 8, then at interval of 7 days for a total of 5-6 dose. Of the nine patients who developed grade IV acute GVHD, two died, the remaining seven recovered after short-term treatment with methotrexate. However, one patient died of subsequent fungal infection. The surviving six patients remained free of GVHD through the last follow-up. Of the 13 patients who suffered from grade III acute GVHD, nine Table 2 Subtypes of cells from G-CSF-primed bone marrow cells and PBSCs infused at transplantation for recipients receiving haploidentical allo-HSCT died, the other four recovered and survived through the end of study.
Chronic GVHD
Among the 150 patients who survived over 100 days after transplantation, 67 developed chronic GVHD, 32 (21.3%). of these had limited chronic GVHD, and 35 (23.3%) had extensive chronic GVHD. The cumulative incidence was 73.6% for total chronic GVHD and 46.9% for extensive chronic GVHD at 2 years after transplantation. Chronic GVHD was diagnosed in 21 of 36 evaluable patients with HLA mismatched in one locus, 20 of 56 patients mismatched in two loci and 26 of 58 patients mismatched in three loci. The development of chronic GVHD was not associated with the age or gender of the patients and donors, the extent of HLA disparity (Figure 2 ) or the stage of disease before transplantation. There was no difference in the incidence of extensive chronic GVHD in patients who received bone marrow, PBSC or both together, containing different numbers of MNC, CD3 þ , CD4 þ , CD8 þ and CD34 þ cells, nor in different age group.
Opportunistic infections
Seventy-eight times of opportunistic infections occurred in 171 patients within the duration of follow-up. The median time for opportunistic infection was 300 days (range: 5-1429 days) after transplantation. The infected loci included lung (29 cases), skin (14 cases), bladder (16 cases), gastrointestinal tract (four cases), central nervous system (four cases) and so on. The infections on skin were caused by varicella zoster virus (14 cases) and herpes simplex virus (four cases). The pathogens found in pneumonia were bacteria in two cases, aspergillus in seven cases, candida albicans in two cases, pneumocystis carinii in two cases and cytomegalovirus in three cases. The other 13 cases of pneumonia were negative in pathogen detection and five cases of them exhibited response for antibiotics. The cumulative incidence of opportunistic infections at 2 years after transplantation was 39.6%, without statistical significance between the standard-and high-risk groups, nor among different age groups.
Relapse and survival
Thirty-two of all 171 patients relapsed after transplantation, 23 of them were from high-risk group, 12 patients achieved complete remission and donor chimerism after donor lymphocyte infusion and survived through the end point of follow-up. The 2 year-probability of relapse 12.2% in the standard-risk group and 38.9% in the high-risk group. Up the 25th November 2005, 111 patients were alive, who were all free of their original leukemia through followup with a median of 682 days (range: 253-1502 days). They were comprised of 66 standard-risk patients, and 45 highrisk patients. Totally 60 out of the 171 patients died, 21 from recurrent leukemia, and 39 from transplant-related complications. The causes of transplantation related death included GVHD in 13 cases, infection in 21 cases and other causes in 5 cases such as heart failure and hepatic failure. The non-relapse mortality was 9.1% for 100 days, 17.4% for 1 year and 19.5% for 2 years in the standard-risk group. In the high-risk group, it was 12.7, 29.4 and 31.1% respectively. The probability of 1-year and 2-year LFS was 79.1 and 68.2% for standard-risk patients and 54. LFS with donor lymphocyte infusion. Hence, the probability of overall survival was as same as that of LFS now. In terms of predictors, LFS was associated with grade III-IV acute GVHD (P ¼ 0.0017), but not with the age of recipients (P ¼ 0.507, Figure 3a and b) , the number of cell subtypes infused (P ¼ 0.842), opportunistic infections after transplantation (P ¼ 0.158), or HLA disparity (Figure 4 ).
Outcome in different age group
All patients were divided into three age groups, younger than 15 years old, 15-35 years old and the others. 15, 52 and 18 patients from these three age groups were in standard-risk group. Those for high-risk group included 15, 50 and 21 patients, respectively. There was no statistically significant difference found in the cumulative incidence of acute GVHD, chronic GVHD, extensive chronic GVHD, opportunistic infections, and nonrelapse mortality in each age group. The cumulative incidence of grade III-IV acute GVHD in patients younger than 15 years (5.0%) was less than that in other age groups (29.9 and 40.0%) (P ¼ 0.044). The probability of LFS for those patients older than 35 years with 2-3 mismatched loci in high-risk group was lower than that for others (P ¼ 0.033, Figure 5 ).
Discussion
For many years, HLA-mismatched HSCT has been limited by three major complications: (1) engraftment failure, (2) 0.00 500.00 1000.00 1500.00 Days after transplantation 0.00 500.00 1000.00 1500.00 Days after transplantation severe GVHD and (3) delayed immune reconstitution. 1, 3, 12 Although T-cell depletion and high-dose infusions of CD34 þ cells reduced the incidence of severe GVHD and improved the rate of engraftment, frequency of relapse and infections remained high and the long-term survival was poor. 13, 14 The reported studies involved small numbers of patients without long-term followup despite several encouraging reports. 14, 15 In the present study, all 171 patients achieved complete donor engraftment. Although the number of T cells in the grafts was more than 1 Â 10 8 cells per kilogram of recipient weight in all patients (Table 2), the incidence of GVHD and deaths from GVHD was lower than expected. The probabilities of 2-year overall survival and LFS were also satisfactory.
Several factors may have contributed to this high rate of engraftment and low incidence of acute GVHD. First, large numbers of T cells were infused, whereas the numbers of CD34 þ cells and MNCs infused were not extraordinarily high (Table 2 ). This suggested that the high dose of T cells at least partially contributed to the efficient engraftment. Second, sequential immunosuppression was used to prevent both GVHD and rejection. CsA was infused from day 9 before transplantation and ATG was used before transplantation. This helped to prevent graft rejection by suppressing or killing host lymphocytes. It may also have induced depletion of infused donor T lymphocytes in vivo and thus lowered the incidence of GVHD. 16 Third, a previous study showed that a combination of CsA and mycophenolate mofetil had a more potent immunosuppressive effect than CsA and methotrexate in preventing graft rejection. 17 Basara et al., 18 reported that mycophenolate mofetil could be used safely and effectively for the prevention of acute GVHD. To enhance the effect of immunosuppression, mycophenolate mofetil was used on day 9 before transplantation. The incidence of GVHD in our study was similar to that observed in HSCT from HLA-matched siblings. This indicates that such an immunosuppression regimen, using CsA, MTX, MMF and ATG, was effective to achieve efficient engraftment and to prevent severe GVHD in haploidentical HSCT.
The grafts we used were mixtures of G-BM and PBSCs, which was used intended to combine the advantage of both elements. It has been shown that PBSCs have two-to threefold more CD34 þ cells and nearly 10-fold more T cells than steady-state bone marrow 19 and they have been shown to accelerate engraftment and decrease the relapse rate. There is also evidence that peripheral T cells, after in vivo G-CSF mobilization, partially lose their ability to induce acute GVHD. 19 Published studies indicated that G-CSFprimed allogeneic bone marrow transplantation (BMT) led to less acute and chronic GVHD, with engraftment comparable to that of PBSCT. 20 Our preliminary results also suggested the existence of quantitative and qualitative differences in immune cells and type I and type II cytokines between G-BM and PBSCs, and the presence of T-cell hyporesponsiveness and easier polarization of T cells from Th 1 to Th 2 in G-BM. [21] [22] [23] These differences may affect the various outcomes of GVHD and graft-versus-leukemia effect (GVL) between G-BM and PBSCs after transplantation. Furthermore, we have found that the mixture of G-BM and PBSCs could form new grafts with different cellular composition and immunological effects. 24 However, no clinical trials have been performed to compare the outcome of transplantation from mixture of G-BM and PBSCs with that from G-BM or PBSCs respectively. Related experimental study was ongoing to clarify the rationale of this regimen.
The major risk factor for leukemia relapse is disease status at the time of transplantation. It is noteworthy that although about one-half of our patients (90 out of 171 patients) had high-risk leukemia, the 2-year probability of relapse was 38.9%. The 2 year LFS was 42.1%. It has not been proved if NK alloreactivity, a biological mechanism unique to mismatched transplantation, may actually be helpful for preventing relapse. In addition, about half of nonrelapse mortality in the present study was caused by infection, which suggested that the quality of immune reconstitution needed to be improved. Research of translational medicine on immune reconstitution are undergoing to clarify the mechanism of our method and to improve clinical outcome.
In the past five years, much progress has been made in HLA-mismatched HSCT without TCD. Quick engraftment, a relatively low incidence of GVHD and a good GVL effect can be achieved without graft failure. These results encourage extending the haploidentical transplant without TCD to patients with an indication for transplantation. The new HSCT regimen described here allows use of haploidentical family members as donors, a strategy likely to be much more important in the future, for the increasing numbers of Chinese patients, and those of other ethnicities, who are the only child in the family.
